Peptides in 2TM · Albiglutide
Episode 04 · 2 minutes · English
Albiglutide: built to last
From Human Genome Sciences in Maryland to a weekly GLP-1 medicine. Explore albumin fusion, Tanzeum and Eperzan, and the cardiovascular evidence that outlasted the medicine’s commercial availability.
English narration and captions. Caption timing is approximate. Translated subtitles are not yet available for this episode.
Published .
Behind the film: Albiglutide references & context
Human Genome Sciences, based in Rockville, Maryland, developed the albumin-fusion approach; GSK acquired worldwide development rights in 2004. Corporate reporting supports this attribution. The film does not identify an individual inventor or claim independent human historical review.
Albiglutide joins two modified human GLP-1 sequences in tandem to human albumin. PDB 1AO6 supplies the native albumin model, not a solved structure of albiglutide. Attachment topology, tissue flow, and receptor signaling are schematic rather than atomically validated or quantitative models.
HARMONY Outcomes enrolled 9,463 people with type 2 diabetes and established cardiovascular disease. The combined endpoint was cardiovascular death, myocardial infarction (heart attack), or stroke. The hazard ratio was 0.78 (95% confidence interval 0.68–0.90), corresponding to a 22% lower relative hazard versus placebo alongside standard care. Events occurred in 338/4,731 versus 428/4,732 participants, approximately 7.1% versus 9.0%, over a median 1.6 years. This is not a 22 percentage-point reduction or a guarantee for an individual patient.
Eperzan’s EU authorization in March 2014 and Tanzeum’s U.S. approval in April 2014 are historical facts, not claims of current local availability. The EU authorization was withdrawn on October 29, 2018 at GSK’s request for commercial reasons. Nausea, diarrhea, and injection-site reactions are selected adverse effects; the archived label contains additional warnings and precautions.
- Human Genome Sciences / SEC, 2004: GSK worldwide development rights; company source
- Human Genome Sciences / SEC, 2011: development context; company source
- FDA: original Tanzeum approval, April 15, 2014
- FDA: archived Tanzeum label, 2016; mechanism and safety
- EMA: Eperzan authorization and commercial withdrawal
- HARMONY Outcomes: Hernandez and colleagues, The Lancet, 2018
- PDB 1AO6: native human serum albumin; Sugio and colleagues, 1999
Location photograph: GSK headquarters, Brentford, England, October 2, 2011, by Maxwell Hamilton, Wikimedia Commons source, CC BY 2.0; cropped, shaded, animated, and titled. This is a historical GSK location, not the Human Genome Sciences discovery laboratory. No endorsement is implied.
Licensed Adobe Stock free-collection media: 410513330 (representative laboratory performers); 297589582 (representative pharmaceutical laboratory); 376080514 (representative glass containers). The vials are not authentic Tanzeum or Eperzan packaging: those products used reconstitution pens. These scenes do not depict the actual albiglutide inventors or production facility. Adobe Stock license terms.
Geographic artwork uses public-domain Natural Earth data: Natural Earth terms. Geographic Europe is not a map of EU membership, current regulatory status, or trial locations. The native albumin structure is PDB data (CC0), credited to Sugio and colleagues, Protein Engineering, 1999; structure publication.
Production includes synthetic narration and series music, original conceptual animations, and AI-generated anatomical heart and brain artwork. These are artistic anatomical models, not patient photographs, diagnostic images, or validated clinical diagrams. Montserrat is used under the SIL Open Font License. Source verification is distinct from scientific assessment or personal human review; no independent human scientific review is claimed.
Educational information, not medical advice. WPF does not sell peptides. Suggest a correction.
Read the English transcript
Some medicines change history even after they leave the market. This is albiglutide: the weekly GLP-1 medicine built around a protein already circulating in your blood.
Its roots lie in Human Genome Sciences, in Rockville, Maryland. The company developed an albumin-fusion approach. In two thousand and four, GSK acquired worldwide development rights.
The design joined two modified GLP-1 sequences to human albumin. A small sequence change resisted breakdown by the enzyme DPP-4. The larger fusion protein slowed clearance, helping the signal last for days.
Injected beneath the skin, it was absorbed into circulation. At GLP-1 receptors, it helped increase insulin release when glucose was high, and reduce glucagon.
Europe authorised Eperzan in March twenty fourteen. The United States approved Tanzeum that April, for adults with type two diabetes. Both names referred to albiglutide.
The Harmony Outcomes trial studied over nine thousand people with type two diabetes and cardiovascular disease. Albiglutide reduced the relative risk of cardiovascular death, heart attack, or stroke by twenty-two percent versus placebo, alongside standard care.
But evidence and availability are different stories. Europe withdrew its authorisation in twenty eighteen at GSK's request, for commercial reasons. Nausea, diarrhea, and injection-site reactions were recognised adverse effects.
Albiglutide left a lasting lesson: molecular engineering can extend a peptide's useful life. Peptides in 2. World Peptide Foundation.